Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novavax, Covid and flu vaccine
Novavax says FDA put hold on combination Covid-flu shot and influenza vaccine; shares plunge
The so-called clinical hold is due to a single report of nerve damage in a patient who received the combination shot in a phase two trial.
US FDA pauses Novavax's trial of combo COVID-flu shot on safety concerns
The U.S. Food and Drug Administration has put Novavax's trial of an experimental COVID-flu vaccine combination on hold after one person who received the shot reported nerve damage, the company said on Wednesday.
Novavax Stock Plunges After FDA Pauses Covid, Flu Vaccine Trials
Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined Covid-flu vaccine and standalone flu inoculation due to safety concerns. Fi
23h
How Bad Is This News for Novavax?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
KQED
3d
Why Getting Your 2024 COVID and Flu Shots Before Halloween Is a Good Idea
After a lengthy COVID-19 surge this summer, the Bay Area is about to enter the winter respiratory virus season. Explore our ...
Daily
3d
Novavax faces setback as USFDA halts COVID-Flu vaccine trial over nerve damage report
Novavax said a participant enrolled in a mid stage study of the combination vaccine last month reported symptoms of motor ...
3d
Novavax’s Regulatory Setback and Mid-Term Underperformance: An Analyst’s Perspective
Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback